Trials / Recruiting
RecruitingNCT04459065
Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- University of Saskatchewan · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IRDye800CW-nimotuzumab | 50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2026-09-01
- Completion
- 2026-10-01
- First posted
- 2020-07-07
- Last updated
- 2024-01-09
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04459065. Inclusion in this directory is not an endorsement.